Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

NCT07166315 | Recruiting

• 1 other identifier: AG9827
• Study Type: observational
• Target: 700
• Locations: 1 country
• Sites: 1

Brief Summary

This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.

Conditions

Axial Spondylarthritis (axSpA); Psoriatic Arthritis (PsA)

Outcome Measures

Primary Outcomes (3)

• Number of participants that have achieved Low Disease Activity (LDA) at 12 months.

  At 12 months

• Number of participants that have achieved Minimal Disease Activity (MDA) at 12 months.

  At 12 months

• Change from baseline in PROM scores at 12 months.

  At 12 months

Study Arms (2)

Axial spondyloarthritis (axSpA)

Patients diagnosed with axial spondyloarthritis (axSpA) who are initiating treatment with bimekizumab, upadacitinib, or a tumour necrosis factor-alpha inhibitor.

Other: observational study

Psoriatic arthritis (PsA)

Patients diagnosed with psoriatic arthritis (PsA) who are initiating treatment with bimekizumab, upadacitinib, risankizumab, guselkumab or a tumour necrosis factor-alpha inhibitor.

Other: observational study

Interventions

observational study OTHER

This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.

Axial spondyloarthritis (axSpA); Psoriatic arthritis (PsA)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Participants will be selected from patients attending NHS hospitals and related healthcare sites targeted across the United Kingdom, including England, Scotland, Wales, and Northern Ireland. These sites are secondary and tertiary care centres where patients with axial spondyloarthritis or psoriatic arthritis are routinely managed by rheumatology services.

You may qualify if:

• Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).
• Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA.
• Participant is aged 18 years or older at enrolment.

You may not qualify if:

• Participation in a clinical trial at enrolment.

Sponsors & Collaborators

• Adelphi Real World: lead

Study Sites (1)

Royal National Hospital for Rheumatic Diseases

Bath, Somerset, BA1 3NG, United Kingdom

RECRUITING

MeSH Terms

Conditions

Arthritis, Psoriatic

Interventions

Observation

Condition Hierarchy (Ancestors)

Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Arthritis; Joint Diseases; Psoriasis; Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Methods; Investigative Techniques

Central Study Contacts

SpA Extend Team

CONTACT

+441625 577 829; arwspaextend@adelphigroup.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 3, 2025
• First Posted: September 10, 2025
• Study Start: July 7, 2025
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): March 1, 2027
• Last Updated: September 10, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)